NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Medical Care Facilities · USD

Cryo-Cell International, Inc. (CCEL) Stock Analysis

Cryo-Cell International, Inc. (CCEL) is a Medical Care Facilities stock listed on NYSE American and quoted in US Dollar.

CCEL

$4.28

+$0.04 (+0.94%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CCEL with… →

CCEL Key Statistics

As of Sep 4, 2026
Trading
Open
$4.20
Previous Close
$4.24
Day's Range
4.20–4.28
52-Week Range
2.72–5.01
Volume
4.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.55
Valuation
Market Cap
$34.51M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
214.00
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.34
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.11
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.31
Financials (FY)
Revenue (FY)
$31.57M−1.31%
Net Income (FY)
−$2.43M−704.18%
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.92%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.06M
1-Year Return
−7.76%
Dividend and dates
Dividend
$0.60+17.19%
Avg Volume
22.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CCEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.42%
2025−50.64%
2024+32.67%
2023+35.93%
2022−58.46%
2021+50.65%
2020+7.99%
2019−4.93%
2018−22.44%
2017+112.06%
2016 (partial year)+16.33%

As of September 4, 2026.

CCEL Revenue and Earnings by Fiscal Year

FY ends November
Fiscal yearRevenueNet incomeNet margin
2025$31.57M−$2.43M−7.7%
2024$31.99M$402.10K1.3%
2023$31.34M−$9.52M−30.4%
2022$30.34M$2.77M9.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$31.57M$24.19M$4.84M−$2.43M−7.7%
2024$31.99M$24.04M$3.79M$402.10K1.3%
2023$31.34M$22.95M$3.49M−$9.52M−30.4%
2022$30.34M$21.54M$4.46M$2.77M9.1%

Annual figures as reported, in the company's reporting currency. As of November 30, 2025.

CCEL Dividend History

$0.40+60.0% vs 2024

Dividends per share, 2025 · 2 payments

YearDividends per sharePaymentsChange
2025$0.402+60.0%
2024$0.251—
2022$0.901—

Most recent payment: $0.20 per share, ex-dividend May 21, 2025. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

CCEL Valuation vs Medical Care Facilities Median

Median of 57 stocks
MetricCCELMedical Care Facilities medianvs median
P/S ratio1.110.9517% above
Profit margin−7.92%3.06%11.0 pts below

Medians across 57 Medical Care Facilities stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Cryo-Cell International, Inc. (CCEL) carries a market capitalisation of $34.51M. It is classified in the Medical Care Facilities industry, within the Healthcare sector. The company reports 72 employees.

The 52-week range on file runs from $2.72 to $5.01. The most recent close on file for CCEL is $4.28, dated September 4, 2026. That is +$0.04 (+0.94%) against the previous close. The latest close sits 57.35% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $31.57M. That is −1.31% against the prior fiscal year, when revenue was $31.99M. The same year closed with a net loss of $2.43M. Profit margin runs at −7.92%. That is 11 percentage points below the Medical Care Facilities median of 3.06%. Trailing earnings per share are −0.31.

Across the 4 fiscal years on file, revenue moves from $30.34M in 2022 to $31.57M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 214. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.34. Measured against sales, the shares trade at 1.11 times revenue. On price-to-sales that is 16.64% above the Medical Care Facilities median of 0.95. The medians here are taken across 57 Medical Care Facilities companies that report the metric.

Beta against the wider market is reported at 0.55. Daily returns over the trailing 10 years annualize to a volatility of 57.83%. Over the trailing twelve months the price has returned −7.76%. Across 10 years the annualized return works out at +2.42%.

Growth & Income

The trailing dividend yield is 17.19%. That is 15.7 percentage points above the Medical Care Facilities median yield of 1.51%. At the indicated rate that is $0.60 a share a year. Dividends are recorded for 3 calendar years; 2025 shows 2 payments totalling $0.40 a share. The year before, 2024, totalled $0.25 a share.

So far in 2026 the price is +24.42%. The strongest complete calendar year on file is 2017 at +112.06%; the weakest is 2022 at −58.46%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Cryo-Cell International, Inc. (CCEL) operates in the Medical Care Facilities industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cryo-Cell International, Inc. CCEL $34.51M —
HCA Healthcare, Inc. HCA $87.68B 13.6
Tenet Healthcare Corporation THC $21.34B 10.2
Fresenius Medical Care AG FMS $12.06B 11.7

The Medical Care Facilities industry average P/E ratio is 19.8x. Cryo-Cell International, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Care Facilities Stocks

HCA

HCA Healthcare, Inc.

$87.68B

 THC

Tenet Healthcare Corporation

$21.34B

 FMS

Fresenius Medical Care AG

$12.06B

 EHC

Encompass Health Corporation

$12.01B

 DVA

DaVita Inc.

$11.74B

 UHS

Universal Health Services, Inc.

$10.00B
View all Medical Care Facilities stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Visit website →